Source: PR Newswire

Press Release: Soligenix : Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - Chairman & CEO of Soligenix

Chairman & CEO

Christopher J. Schaber

CEO Approval Rating

88/100

Soligenix is a late-stage biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases. Read more